Salta alla navigazione principale Salta alla ricerca Salta al contenuto principale

Busulfan–fludarabine- or treosulfan–fludarabine-based conditioning before allogeneic HSCT from matched sibling donors in paediatric patients with sickle cell disease: A study on behalf of the EBMT Paediatric Diseases and Inborn Errors Working Parties

  • Annamária Cseh
  • , Jacques-Emmanuel Galimard
  • , Josu De La Fuente
  • , Antonella Isgro
  • , Marco Zecca
  • , Birgit Garwer
  • , Alexandra Biffi
  • , Mahmoud Aljurf
  • , Mikael Sundin
  • , Cristina Belendez
  • , Franco Locatelli
  • , Adriana Balduzzi
  • , Sarah Lawson
  • , Henrik Sengeloev
  • , Marianne Ifversen
  • , Riccardo Saccardi
  • , Robert Wynn
  • , Arjan C. Lankester
  • , Selim Corbacioglu
  • , Christina Peters
  • St. Anna Children's Cancer Research Institute
  • European Society for Blood and Marrow Transplantation (EBMT) Statistical Unit
  • St. Mary's Hospital
  • University of Rome Tor Vergata
  • University of Padua
  • University of Hamburg
  • Clinica di Oncoematologia Pediatrica
  • King Faisal Specialist Hospital and Research Centre
  • Karolinska Institutet
  • Hospital Univ.Materno Infantil Gregorio Marañon
  • University of Milan - Bicocca
  • Birmingham Women's and Children's NHS Foundation Trust
  • University of Copenhagen
  • Azienda Ospedaliera Careggi
  • Manchester University NHS Foundation Trust
  • Leiden University
  • University of Regensburg

Risultato della ricerca: Contributo in rivistaArticolo

Lingua originaleInglese
pagine (da-a)1-5
Numero di pagine5
RivistaBritish Journal of Haematology
DOI
Stato di pubblicazionePubblicato - 2023

Keywords

  • HSCT
  • sickle cell disease

Cita questo